《新股表現》海普瑞藥業(09989.HK)暗盤高開10%報20.25元
根據輝立交易平台顯示,明天掛牌的海普瑞藥業(09989.HK)暗盤高開10%報20.25元,最高見21元遇壓,現造18.42元,較上市價18.4元,僅高0.1%,成交154萬股。
海普瑞是內地領先製藥公司,在製藥領域、創新生物科技領域及CDMO領域擁有全球業務。根據弗若斯特沙利文資料,按2019年全球銷售額計,海普瑞是內地最大及全球第三大依諾肝素鈉注射液生產商及銷售商,佔據6.5%全球市場份額。自2010年5月起,海普瑞A股(002399.SZ)已於深交所上市。
海普瑞今次來港上市合共發售逾2.2億股H股,並已引入OrbiMed Funds、AVICT、歐萬達基金、3W及Anlan Funds為基石投資者,合共認購4,630.75萬股H股(設有6個月禁售期);其中10%公開發售獲逾68倍超購,已啟動回撥機制佔比增至40%,認購一手中籤率40%;股份以招股範圍(18.4-20.6元)下限定價,料集資淨額約38.06億元,主要用作還債、於歐洲及其他市場發展營銷網絡和基建、提升研發生產能力及用於創新藥投資等。上市聯席保薦人大摩及高盛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.